Auriga Partners

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Patrowl is a cybersecurity company that specializes in automating vulnerability detection and remediation. Designed by cybersecurity experts, the platform employs artificial intelligence to conduct continuous penetration tests, enabling real-time identification of both known and shadow IT assets and vulnerabilities. Patrowl provides users with a clear visualization of their overall security posture and offers tailored solutions for remediation, which can be easily implemented or communicated to relevant teams. The platform also allows for quick verification of fixes through retesting, ensuring that vulnerabilities have been addressed effectively. By simplifying cybersecurity processes, Patrowl aims to enhance clients' security measures and deter cybercriminals, making effective cybersecurity accessible to a broader audience.

Vade Secure is a leading global provider of advanced email security solutions, specializing in anti-phishing, malware, and ransomware protection through heuristic filtering. The company’s language-independent technology analyzes incoming emails, including links, attachments, and content, to detect and neutralize threats in real-time. Vade Secure also addresses low-priority emails through its Graymail Management feature, which automatically filters out ads, social media notifications, and newsletters, enhancing user experience. With a user base exceeding 500 million mailboxes across 76 countries, Vade Secure's solutions are widely adopted by major internet service providers, original equipment manufacturers, and enterprises worldwide. The company operates in five countries, including the USA, Canada, France, Hong Kong, and Japan, providing round-the-clock support to its clients.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Flash Therapeutics is a biotechnology company based in Labège, France, specializing in gene and cell-based therapies through its proprietary lentiviral platform. Established in 2005 and formerly known as Vectalys SAS, the company focuses on developing advanced viral vector technologies to transduce difficult-to-transfect cells, including primary cells and stem cells. Flash Therapeutics offers a range of services, including gene silencing, gene over-expression, cell-based assay development, and protein expression. It also conducts preclinical trials for gene therapy and produces concentrated viral vectors for research purposes. The company is committed to creating innovative solutions for drug screening and the development of cellular and animal models to validate candidate genes.

EnobraQ is a start-up established in 2015, originating from a pre-competitive research initiative backed by Toulouse White Biotechnology. The company focuses on developing innovative technologies that utilize carbon dioxide as an industrial fermentation feedstock. EnobraQ's solutions address both ecological and economic challenges, targeting a variety of markets, including nutrition, agri-food, cosmetics, pharmacology, and bioplastics. Through its advancements, EnobraQ aims to contribute to sustainable practices in multiple industries by transforming CO2 into valuable products.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, that specializes in the research and development of lytic bacteriophages for therapeutic and diagnostic purposes, particularly in the context of antibiotic resistance. Established in 2006, the company is dedicated to creating personalized phage therapies aimed at treating bacterial infections. It has developed several banks of bacteriophages, including those targeting Escherichia coli, and has initiated multicenter clinical trials across Europe to assess the efficacy of phage therapy in treating infected burn wounds. By harnessing the natural ability of bacteriophages to infect and eliminate bacteria without affecting human cells, Pherecydes Pharma aims to provide innovative solutions for combating a wide range of bacterial threats, including multi-resistant and emergent strains.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor and electronic applications, focusing on damascene through silicon vias and MEMS. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, the company is based in Massy, France. Aveni's core offerings include Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been successfully implemented in manufacturing for processes at and below the 14 nm node and for high aspect ratios. Aveni collaborates with various research and development centers and leading global manufacturers, leveraging its expertise in surface science, chemistry, electrochemistry, and materials science to enhance device performance and yield in the semiconductor and renewable energy sectors.

Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwide understand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues. Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest. Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects.

VitaDX is a healthcare technology company specializing in the early detection of cancer. It leverages artificial intelligence and fluorescence imaging to develop innovative diagnostic tools. The company's flagship product, VisioCyt®, is designed to identify bladder cancer from urine samples, aiming to enhance the performance of conventional urinary cytology.

Nosopharm SAS is a biotechnology company focused on the research and development of innovative antibacterial molecules to combat the growing threat of multidrug-resistant infections, particularly in hospital settings. Established in 2009 and headquartered in Nimes, France, Nosopharm specializes in Odilorhabdins, a novel class of antibiotics designed to target resistant gram-negative pathogens such as Escherichia coli and Pseudomonas aeruginosa. The company's lead product, NOSO-95179, is a first-generation Odilorhabdin aimed at treating Carbapenem-resistant Enterobacteriaceae infections, while NOSO-95400 represents a second-generation option for addressing a broader range of multidrug-resistant bacteria. Nosopharm employs an innovative drug discovery platform that leverages the medicinal properties of microbial biodiversity, particularly focusing on metabolites from the bacterial genera Xenorhabdus and Photorhabdus. Through its dedicated efforts, Nosopharm seeks to address the critical medical need for effective treatments against hospital-acquired infections.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.

One More Company, Inc. is a U.S.-based corporation specializing in contextual intelligence email services, with a focus on enhancing the email experience for users. Its flagship product, Senders™, acts like Caller ID for email, providing recipients with essential information about the sender directly within the email, regardless of the platform or device used. Senders™ is a patent-pending service that prioritizes user privacy and security, adhering to a digital ethics framework centered on consumer control and transparency. The company, founded by experienced executives from notable tech firms, aims to filter valuable messaging from irrelevant noise, offering simple and intuitive solutions for individuals and businesses. One More Company does not rely on advertising revenue or data selling, placing the interests of its users at the forefront of its mission. With offices in New York and Paris, One More Company is dedicated to creating a positive consumer experience through thoughtful product design that incorporates privacy and security from the outset.

Nexthink, established in 2004, specializes in digital experience management, focusing on the end-user perspective. Headquartered in Switzerland with global operations, the company offers a real-time analytics platform that transforms endpoint data into actionable insights. This enables organizations to enhance business productivity, manage incidents and changes effectively, and measure digital workplace experience using the Digital Experience Score system. Nexthink serves a diverse range of industries, including finance, healthcare, and manufacturing, empowering IT teams to create highly productive digital workplaces for employees.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor and electronic applications, focusing on damascene through silicon vias and MEMS. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, the company is based in Massy, France. Aveni's core offerings include Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been successfully implemented in manufacturing for processes at and below the 14 nm node and for high aspect ratios. Aveni collaborates with various research and development centers and leading global manufacturers, leveraging its expertise in surface science, chemistry, electrochemistry, and materials science to enhance device performance and yield in the semiconductor and renewable energy sectors.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, that specializes in the research and development of lytic bacteriophages for therapeutic and diagnostic purposes, particularly in the context of antibiotic resistance. Established in 2006, the company is dedicated to creating personalized phage therapies aimed at treating bacterial infections. It has developed several banks of bacteriophages, including those targeting Escherichia coli, and has initiated multicenter clinical trials across Europe to assess the efficacy of phage therapy in treating infected burn wounds. By harnessing the natural ability of bacteriophages to infect and eliminate bacteria without affecting human cells, Pherecydes Pharma aims to provide innovative solutions for combating a wide range of bacterial threats, including multi-resistant and emergent strains.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, that specializes in the research and development of lytic bacteriophages for therapeutic and diagnostic purposes, particularly in the context of antibiotic resistance. Established in 2006, the company is dedicated to creating personalized phage therapies aimed at treating bacterial infections. It has developed several banks of bacteriophages, including those targeting Escherichia coli, and has initiated multicenter clinical trials across Europe to assess the efficacy of phage therapy in treating infected burn wounds. By harnessing the natural ability of bacteriophages to infect and eliminate bacteria without affecting human cells, Pherecydes Pharma aims to provide innovative solutions for combating a wide range of bacterial threats, including multi-resistant and emergent strains.

Theranexus is a clinical-stage pharmaceutical company based in France that focuses on developing innovative drug candidates for central nervous system (CNS) disorders. The company aims to address significant medical needs in brain disorders through its unique therapeutics platform, which combines two distinct drugs to simultaneously target neurons and glial cells. Among its drug candidates are THN102, designed to treat excessive daytime sleepiness in Parkinson's disease; THN201, aimed at treating neurocognitive disorders associated with Alzheimer's disease; and THN101, developed for neuropathic pain. Theranexus's approach seeks to enhance therapeutic efficacy by leveraging the interplay between neuronal and glial cell activity.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor and electronic applications, focusing on damascene through silicon vias and MEMS. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, the company is based in Massy, France. Aveni's core offerings include Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been successfully implemented in manufacturing for processes at and below the 14 nm node and for high aspect ratios. Aveni collaborates with various research and development centers and leading global manufacturers, leveraging its expertise in surface science, chemistry, electrochemistry, and materials science to enhance device performance and yield in the semiconductor and renewable energy sectors.

Median Technologies SA is a company that specializes in developing and marketing software products for medical image analysis, primarily focused on oncology. Founded in 2002 and based in Valbonne, France, the company offers two main platforms: iBiopsy, which utilizes AI for biomarker identification and patient profiling through CT scans, and iSee, designed for image analysis and management in clinical trials. Median Technologies aims to enhance the diagnosis of cancer patients and assess their treatment responses by standardizing and automating medical image interpretation. The company operates in two main markets: drug development and patient care, and collaborates with a contract research organization to provide integrated imaging services for clinical trials. Additionally, it has partnered with Canon to innovate new imaging technologies for the patient care sector.

Amoeba is a France-based company dedicated to the development, production, and commercialization of environmentally friendly biocide water treatment chemicals. Its primary product, BIOMEBA, utilizes the biocidal properties of the microorganism Willaertia magna to effectively address bacterial risks in cooling towers, particularly within the industrial sector. Through its innovative approach, Amoeba aims to provide sustainable solutions for water treatment challenges, positioning itself as a leader in the green biocide market.

Nexthink, established in 2004, specializes in digital experience management, focusing on the end-user perspective. Headquartered in Switzerland with global operations, the company offers a real-time analytics platform that transforms endpoint data into actionable insights. This enables organizations to enhance business productivity, manage incidents and changes effectively, and measure digital workplace experience using the Digital Experience Score system. Nexthink serves a diverse range of industries, including finance, healthcare, and manufacturing, empowering IT teams to create highly productive digital workplaces for employees.

Fab’entech, founded in 2009 in Lyon, France, is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂], targeting emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab’entech aims to provide healthcare institutions with effective treatments for urgent medical situations. As a member of the LyonBiopôle cluster, the company is positioned within a vibrant network dedicated to advancing biopharmaceutical innovation.

Wallix is a cybersecurity software company based in France, specializing in privileged access management solutions under the name WALLIX Bastion. The company addresses the growing demand for security in response to regulatory changes and increasing cyber threats, offering tools to protect critical IT assets, including data, servers, and connected devices. Its product suite includes a session manager for real-time monitoring of privileged users, a password manager for access governance, and an access manager that provides a centralized overview of user activities. Wallix has received first-level security certification from France’s National Cybersecurity Agency, demonstrating its commitment to regulatory compliance. With a customer base of over 770 companies and organizations, including notable clients like McDonald’s and Dassault Aviation, Wallix operates through a network of more than 160 resellers and integrators across Europe and EMEA, positioning itself as a leader in the privileged access management market.

Convertigo S.A. is a French company that specializes in enterprise mashups and mobile application development. Founded in 1994 and previously known as Twinsoft, Convertigo offers a comprehensive platform that includes the Convertigo Enterprise Mashup Server (C-EMS) and Convertigo Mobilizer for mobile enterprise application integration. The C-EMS facilitates the creation of WEB 2.0 composite applications by allowing businesses to reuse their existing assets and combine various components, such as built-in widgets and DataWidgets. Key features include the Mashup Composer, Web Integrator for migrating applications to service-oriented architecture (SOA), and tools for legacy application access and modernization. Convertigo is recognized for its innovative low-code and no-code solutions, enabling organizations to connect enterprise data and efficiently develop, deploy, and manage mobile and web applications. The company's technology has been successfully implemented in over 50,000 installations, serving major global clients in various industries.

eXo Platform SAS is a developer of open-source digital collaboration software that specializes in Java middleware for cloud services. Founded in 2003 and headquartered in Paris, France, eXo provides a range of solutions including its core eXo Platform, which facilitates the expansion of existing applications, and eXo Portal, which offers a unified access point for personalized content and applications. The company’s offerings also include tools for web content management, workflow design, and social engagement, as well as the eXo Collaboration Suite and eXo Knowledge Suite for enhancing organizational knowledge sharing. eXo's products are utilized by a diverse array of organizations across sectors such as government, finance, and telecommunications, supported by strategic partnerships with industry leaders like Red Hat. In addition to its Paris headquarters, eXo has offices in San Francisco, Vannes Cedex, Hanoi, Tunis, and Cherkassy, enabling it to operate on a global scale.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Nosopharm SAS is a biotechnology company focused on the research and development of innovative antibacterial molecules to combat the growing threat of multidrug-resistant infections, particularly in hospital settings. Established in 2009 and headquartered in Nimes, France, Nosopharm specializes in Odilorhabdins, a novel class of antibiotics designed to target resistant gram-negative pathogens such as Escherichia coli and Pseudomonas aeruginosa. The company's lead product, NOSO-95179, is a first-generation Odilorhabdin aimed at treating Carbapenem-resistant Enterobacteriaceae infections, while NOSO-95400 represents a second-generation option for addressing a broader range of multidrug-resistant bacteria. Nosopharm employs an innovative drug discovery platform that leverages the medicinal properties of microbial biodiversity, particularly focusing on metabolites from the bacterial genera Xenorhabdus and Photorhabdus. Through its dedicated efforts, Nosopharm seeks to address the critical medical need for effective treatments against hospital-acquired infections.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Firalis is a biotechnology company specializing in the discovery, development, and regulatory qualification of novel biomarkers aimed at enhancing diagnostics for various diseases. The company focuses on biomarkers related to inflammatory disorders, including common conditions like atherosclerosis and rheumatoid arthritis, as well as rare diseases such as systemic or autoimmune vasculitis. Firalis is particularly invested in addressing drug-induced organ injuries in major targets like the kidneys, liver, and vasculature. By leveraging a unique network of clinical centers of excellence, Firalis conducts biomarker qualification studies to ensure high success potential for its diagnostic kits. The company is headquartered in Huningue, France, strategically located in BioValley, which is known for its proximity to significant pharmaceutical hubs in Europe. Through its innovative biomarker services, Firalis aims to improve patient outcomes, enhance therapeutic decisions, and reduce overall healthcare costs.

Miliboo is a furniture design and manufacturing company based in Pringy, France, founded in 2005. The company specializes in contemporary furniture, offering a diverse range of products that includes sofas, armchairs, bar stools, office chairs, dining tables, storage solutions, bathroom furniture, and garden furniture. Additionally, Miliboo provides decor items and furniture specifically designed for children. With a focus on modern aesthetics and functional design, Miliboo aims to cater to a variety of consumer needs within the furniture market.

Bonitasoft is a software company specializing in open-source business process management (BPM) solutions. Founded in 2001 and headquartered in Grenoble, France, with offices in San Francisco and Paris, the company offers Bonita Open Solution, an end-to-end BPM platform for designing, developing, executing, and monitoring business processes. This solution includes Bonita Studio for graphical process design and Bonita Execution Engine for integrating new services or standards. Additionally, Bonitasoft provides BonitaCloud Platform-as-a-Service, enabling developers to build and run applications in various environments. Their products cater to corporate functions such as HR, finance, quality management, and IT management across industries like education, energy, healthcare, manufacturing, and retail worldwide. The company also offers support services for application development and delivery, along with training, advising, and consulting services.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor and electronic applications, focusing on damascene through silicon vias and MEMS. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, the company is based in Massy, France. Aveni's core offerings include Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been successfully implemented in manufacturing for processes at and below the 14 nm node and for high aspect ratios. Aveni collaborates with various research and development centers and leading global manufacturers, leveraging its expertise in surface science, chemistry, electrochemistry, and materials science to enhance device performance and yield in the semiconductor and renewable energy sectors.

SuperSonic Imagine SA is a medical technology company based in Aix-en-Provence, France, specializing in the development and manufacture of ultrasound imaging systems. Founded in 2005, the company is recognized for its Aixplorer system, which delivers high-definition, high-contrast imaging crucial for diagnosing and monitoring various conditions, including breast, prostate, and thyroid cancers, as well as liver diseases. SuperSonic Imagine also offers the ShearWave technology platform, which focuses on quantitative elastography for assessing tissue elasticity. The company operates primarily in France, the United States, and China, and distributes its products through a network of offices and partners across various countries, including Belgium, Germany, and the United Kingdom. As a subsidiary of Hologic Hub Ltd, SuperSonic Imagine continues to innovate in the field of medical imaging technology, enhancing the capabilities of healthcare practitioners.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Codenvy is a provider of a cloud development platform that facilitates the coding, building, and testing of applications. The company offers a cloud-based development environment that transforms the traditional local desktop setup, which includes the editor, builder, and tester runtimes, by logically separating it from the physical environment and relocating it to the cloud. This innovative approach enables enterprises to access on-demand workspaces that promote collaboration and eliminate constraints typically associated with local development environments.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Wallix is a cybersecurity software company based in France, specializing in privileged access management solutions under the name WALLIX Bastion. The company addresses the growing demand for security in response to regulatory changes and increasing cyber threats, offering tools to protect critical IT assets, including data, servers, and connected devices. Its product suite includes a session manager for real-time monitoring of privileged users, a password manager for access governance, and an access manager that provides a centralized overview of user activities. Wallix has received first-level security certification from France’s National Cybersecurity Agency, demonstrating its commitment to regulatory compliance. With a customer base of over 770 companies and organizations, including notable clients like McDonald’s and Dassault Aviation, Wallix operates through a network of more than 160 resellers and integrators across Europe and EMEA, positioning itself as a leader in the privileged access management market.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

Eptica S.A. is a company that specializes in designing and developing customer relationship management (CRM) software for business-to-business marketplaces. Founded in 2001 and headquartered in Boulogne-Billancourt, France, Eptica offers solutions that facilitate real-time interactions between enterprises, clients, suppliers, and partners through multiple digital channels. Its software includes features for social customer service, email management, chat, and knowledge management, enabling organizations to enhance customer engagement and drive sales through personalized communication. Additionally, Eptica provides professional services such as technical support, training, and consulting, catering to various sectors including banking, insurance, retail, tourism, and public institutions. As of October 2019, Eptica operates as a subsidiary of Enghouse Systems Limited.

AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.

Neolane is a provider of conversational marketing technology, specializing in marketing automation and cross-channel campaign management software and services for both business-to-business and business-to-consumer marketers. The company's solutions enable organizations to build and maintain one-on-one customer dialogues throughout the customer lifecycle, aiming to enhance revenue and improve marketing efficiency. Neolane's technology has been adopted by over 400 leading global companies, including Alcatel Lucent, Barnes & Noble, Orange, Sears Canada, Sephora Europe, and Sony Music. The company is recognized for helping its clients quickly adapt to new customer engagement challenges and capitalize on opportunities more swiftly than their competitors.

IDbyME is a fashion and clothing company offering fully customizable items under the MoodbyMe brand.

CYTOO SA is a life sciences company based in Grenoble, France, specializing in micropattern-enhanced cell-based assays aimed at improving cellular analysis for the research community. Founded in 2008, the company develops, manufactures, and commercializes innovative technologies, including CYTOO chips and CYTOOplates, which utilize glass coverslips and microplates featuring adhesive micropatterns for various applications such as immunofluorescence assays and high-resolution live microscopy. Their products are designed to enhance the physiological relevance of cellular models, thereby reducing variability and increasing the reliability of assay results. CYTOO's technologies facilitate studies in areas such as cell shape, cytoskeleton organization, cell polarity, and quantitative cell phenotyping, catering to a diverse range of research goals. In addition to their product offerings, CYTOO provides assay development services to further support researchers in their experimental endeavors.

Wallix is a cybersecurity software company based in France, specializing in privileged access management solutions under the name WALLIX Bastion. The company addresses the growing demand for security in response to regulatory changes and increasing cyber threats, offering tools to protect critical IT assets, including data, servers, and connected devices. Its product suite includes a session manager for real-time monitoring of privileged users, a password manager for access governance, and an access manager that provides a centralized overview of user activities. Wallix has received first-level security certification from France’s National Cybersecurity Agency, demonstrating its commitment to regulatory compliance. With a customer base of over 770 companies and organizations, including notable clients like McDonald’s and Dassault Aviation, Wallix operates through a network of more than 160 resellers and integrators across Europe and EMEA, positioning itself as a leader in the privileged access management market.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Bonitasoft is a software company specializing in open-source business process management (BPM) solutions. Founded in 2001 and headquartered in Grenoble, France, with offices in San Francisco and Paris, the company offers Bonita Open Solution, an end-to-end BPM platform for designing, developing, executing, and monitoring business processes. This solution includes Bonita Studio for graphical process design and Bonita Execution Engine for integrating new services or standards. Additionally, Bonitasoft provides BonitaCloud Platform-as-a-Service, enabling developers to build and run applications in various environments. Their products cater to corporate functions such as HR, finance, quality management, and IT management across industries like education, energy, healthcare, manufacturing, and retail worldwide. The company also offers support services for application development and delivery, along with training, advising, and consulting services.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

Isocell SA is a biotechnology company based in Paris, France, specializing in the development and manufacture of nutritional supplements. The company offers a range of products designed to support health and well-being, including GliSODine VITALITE for energy recovery, GliSODin COMPLEX, which protects the activity of SuperOxide Dismutase in intestinal cells, and GliSODine, an antioxidant that combats oxidative stress related to aging. Additionally, Isocell provides GliSODine DEFENSES to enhance immune function, GliSODine DRAINANTE to aid digestion and detoxification, and GliSODine MOISTURIZING for skin health. Other offerings include GliSODine SOLAIRE, which prepares the skin for sun exposure, and GliSODine DETOXIFIANTE for overall purification and revitalization. Founded in 2001, Isocell serves customers in France and internationally, including markets in the United States, Japan, and Europe. The company also has a professional line of nutricosmetics known as GliSODin Skin Nutrients, launched in 2008, which focuses on providing essential nutrients to protect the skin from oxidative stress.

Founded in 2001, Availpro is a prominent provider of e-booking software solutions for the hospitality industry. The company offers an integrated online distribution system that enables hotel owners to enhance occupancy rates and revenue while reducing costs. Availpro's innovative tools assist managers in optimizing their online distribution, maximizing commission-free bookings from their official websites, and facilitating informed pricing decisions. With a team of 75 professionals, Availpro specializes in creating and implementing connectivity solutions that link various software systems and platforms. The company partners with over 300 global entities, including major online travel agencies, meta-search engines, and property management systems, to streamline the distribution process. Availpro’s commitment to simplicity and efficiency has established it as a reliable and high-performance online distribution tool in the hotel industry.

Cellnovo is a medical device company focused on diabetes management. The company develops and markets an integrated system that connects various components of diabetes care through mobile technology. Its product portfolio includes a cordless micro-pump, an integrated monitoring device, and a cellular handset equipped with a touch screen and an embedded blood glucose meter. This innovative system allows for automatic data transmission, enabling patients and healthcare providers to effectively monitor the patient's condition in real-time.

Miliboo is a furniture design and manufacturing company based in Pringy, France, founded in 2005. The company specializes in contemporary furniture, offering a diverse range of products that includes sofas, armchairs, bar stools, office chairs, dining tables, storage solutions, bathroom furniture, and garden furniture. Additionally, Miliboo provides decor items and furniture specifically designed for children. With a focus on modern aesthetics and functional design, Miliboo aims to cater to a variety of consumer needs within the furniture market.

Median Technologies SA is a company that specializes in developing and marketing software products for medical image analysis, primarily focused on oncology. Founded in 2002 and based in Valbonne, France, the company offers two main platforms: iBiopsy, which utilizes AI for biomarker identification and patient profiling through CT scans, and iSee, designed for image analysis and management in clinical trials. Median Technologies aims to enhance the diagnosis of cancer patients and assess their treatment responses by standardizing and automating medical image interpretation. The company operates in two main markets: drug development and patient care, and collaborates with a contract research organization to provide integrated imaging services for clinical trials. Additionally, it has partnered with Canon to innovate new imaging technologies for the patient care sector.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

SuperSonic Imagine SA is a medical technology company based in Aix-en-Provence, France, specializing in the development and manufacture of ultrasound imaging systems. Founded in 2005, the company is recognized for its Aixplorer system, which delivers high-definition, high-contrast imaging crucial for diagnosing and monitoring various conditions, including breast, prostate, and thyroid cancers, as well as liver diseases. SuperSonic Imagine also offers the ShearWave technology platform, which focuses on quantitative elastography for assessing tissue elasticity. The company operates primarily in France, the United States, and China, and distributes its products through a network of offices and partners across various countries, including Belgium, Germany, and the United Kingdom. As a subsidiary of Hologic Hub Ltd, SuperSonic Imagine continues to innovate in the field of medical imaging technology, enhancing the capabilities of healthcare practitioners.

Eve.com specializes in massively multiplayer online roleplaying games (MMORPGs), boasting a diverse portfolio that includes popular titles such as Eve Online, Eve Valkyrie, Gunjack, Dust 514, and Eve Universe. The company focuses on creating immersive gaming experiences that engage players in expansive virtual worlds, fostering community interaction and collaboration. Through its innovative approach to game design and storytelling, Eve.com has established a strong presence in the gaming industry, appealing to a dedicated audience of gamers.

Nexthink, established in 2004, specializes in digital experience management, focusing on the end-user perspective. Headquartered in Switzerland with global operations, the company offers a real-time analytics platform that transforms endpoint data into actionable insights. This enables organizations to enhance business productivity, manage incidents and changes effectively, and measure digital workplace experience using the Digital Experience Score system. Nexthink serves a diverse range of industries, including finance, healthcare, and manufacturing, empowering IT teams to create highly productive digital workplaces for employees.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

Ekinops is a company that specializes in next-generation optical transport solutions aimed at service providers and private networks globally. It offers a range of carrier-grade products, including the EKINOPS 360 platform, which is designed for metro, regional, and long-haul applications. Ekinops leverages its expertise in 10G, 100G, and 200G transmission technologies to enhance data transport capacity over various networks, including dark fiber, CWDM, DWDM, and SONET/SDH. Its solutions are engineered to optimize optical networks, enabling operators to efficiently manage data transmission and aggregation while ensuring high reliability through advanced Forward Error Correction capabilities.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

eXo Platform SAS is a developer of open-source digital collaboration software that specializes in Java middleware for cloud services. Founded in 2003 and headquartered in Paris, France, eXo provides a range of solutions including its core eXo Platform, which facilitates the expansion of existing applications, and eXo Portal, which offers a unified access point for personalized content and applications. The company’s offerings also include tools for web content management, workflow design, and social engagement, as well as the eXo Collaboration Suite and eXo Knowledge Suite for enhancing organizational knowledge sharing. eXo's products are utilized by a diverse array of organizations across sectors such as government, finance, and telecommunications, supported by strategic partnerships with industry leaders like Red Hat. In addition to its Paris headquarters, eXo has offices in San Francisco, Vannes Cedex, Hanoi, Tunis, and Cherkassy, enabling it to operate on a global scale.

IDbyME is a fashion and clothing company offering fully customizable items under the MoodbyMe brand.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

CYTOO SA is a life sciences company based in Grenoble, France, specializing in micropattern-enhanced cell-based assays aimed at improving cellular analysis for the research community. Founded in 2008, the company develops, manufactures, and commercializes innovative technologies, including CYTOO chips and CYTOOplates, which utilize glass coverslips and microplates featuring adhesive micropatterns for various applications such as immunofluorescence assays and high-resolution live microscopy. Their products are designed to enhance the physiological relevance of cellular models, thereby reducing variability and increasing the reliability of assay results. CYTOO's technologies facilitate studies in areas such as cell shape, cytoskeleton organization, cell polarity, and quantitative cell phenotyping, catering to a diverse range of research goals. In addition to their product offerings, CYTOO provides assay development services to further support researchers in their experimental endeavors.

Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.

Bonitasoft is a software company specializing in open-source business process management (BPM) solutions. Founded in 2001 and headquartered in Grenoble, France, with offices in San Francisco and Paris, the company offers Bonita Open Solution, an end-to-end BPM platform for designing, developing, executing, and monitoring business processes. This solution includes Bonita Studio for graphical process design and Bonita Execution Engine for integrating new services or standards. Additionally, Bonitasoft provides BonitaCloud Platform-as-a-Service, enabling developers to build and run applications in various environments. Their products cater to corporate functions such as HR, finance, quality management, and IT management across industries like education, energy, healthcare, manufacturing, and retail worldwide. The company also offers support services for application development and delivery, along with training, advising, and consulting services.

Convertigo S.A. is a French company that specializes in enterprise mashups and mobile application development. Founded in 1994 and previously known as Twinsoft, Convertigo offers a comprehensive platform that includes the Convertigo Enterprise Mashup Server (C-EMS) and Convertigo Mobilizer for mobile enterprise application integration. The C-EMS facilitates the creation of WEB 2.0 composite applications by allowing businesses to reuse their existing assets and combine various components, such as built-in widgets and DataWidgets. Key features include the Mashup Composer, Web Integrator for migrating applications to service-oriented architecture (SOA), and tools for legacy application access and modernization. Convertigo is recognized for its innovative low-code and no-code solutions, enabling organizations to connect enterprise data and efficiently develop, deploy, and manage mobile and web applications. The company's technology has been successfully implemented in over 50,000 installations, serving major global clients in various industries.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Ekinops is a company that specializes in next-generation optical transport solutions aimed at service providers and private networks globally. It offers a range of carrier-grade products, including the EKINOPS 360 platform, which is designed for metro, regional, and long-haul applications. Ekinops leverages its expertise in 10G, 100G, and 200G transmission technologies to enhance data transport capacity over various networks, including dark fiber, CWDM, DWDM, and SONET/SDH. Its solutions are engineered to optimize optical networks, enabling operators to efficiently manage data transmission and aggregation while ensuring high reliability through advanced Forward Error Correction capabilities.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

SuperSonic Imagine SA is a medical technology company based in Aix-en-Provence, France, specializing in the development and manufacture of ultrasound imaging systems. Founded in 2005, the company is recognized for its Aixplorer system, which delivers high-definition, high-contrast imaging crucial for diagnosing and monitoring various conditions, including breast, prostate, and thyroid cancers, as well as liver diseases. SuperSonic Imagine also offers the ShearWave technology platform, which focuses on quantitative elastography for assessing tissue elasticity. The company operates primarily in France, the United States, and China, and distributes its products through a network of offices and partners across various countries, including Belgium, Germany, and the United Kingdom. As a subsidiary of Hologic Hub Ltd, SuperSonic Imagine continues to innovate in the field of medical imaging technology, enhancing the capabilities of healthcare practitioners.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Bag Tech is a manufacturer specializing in the design and production of a diverse range of bags and backpacks. Located in Sialkot, Pakistan, the company operates within a facility that spans over 10,000 square feet, employing skilled craftsmen who use modern technology to ensure high-quality manufacturing. Bag Tech offers a wide variety of products, including kit bags for sports like cricket, hockey, and martial arts, as well as practical options such as gym bags, laptop bags, and school bags. The company's focus on durability and practicality allows it to provide wholesale prices to its clients, catering to various needs in the bag market.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe chronic inflammatory diseases and autoimmune disorders. The company’s innovative approach includes the creation of Treg-based therapies with chimeric antigen receptors (CAR), targeting conditions such as graft rejection in solid organ transplantation, bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease. TxCell has completed a Phase I/II study for its therapy in Crohn's disease and plans to advance further studies, including a Phase IIb trial in the same patient population and additional trials for rheumatoid arthritis. The company collaborates with various research institutions, enhancing its development capabilities. As of October 2018, TxCell operates as a subsidiary of Sangamo Therapeutics, Inc.

TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.

Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

Ekinops is a company that specializes in next-generation optical transport solutions aimed at service providers and private networks globally. It offers a range of carrier-grade products, including the EKINOPS 360 platform, which is designed for metro, regional, and long-haul applications. Ekinops leverages its expertise in 10G, 100G, and 200G transmission technologies to enhance data transport capacity over various networks, including dark fiber, CWDM, DWDM, and SONET/SDH. Its solutions are engineered to optimize optical networks, enabling operators to efficiently manage data transmission and aggregation while ensuring high reliability through advanced Forward Error Correction capabilities.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Median Technologies SA is a company that specializes in developing and marketing software products for medical image analysis, primarily focused on oncology. Founded in 2002 and based in Valbonne, France, the company offers two main platforms: iBiopsy, which utilizes AI for biomarker identification and patient profiling through CT scans, and iSee, designed for image analysis and management in clinical trials. Median Technologies aims to enhance the diagnosis of cancer patients and assess their treatment responses by standardizing and automating medical image interpretation. The company operates in two main markets: drug development and patient care, and collaborates with a contract research organization to provide integrated imaging services for clinical trials. Additionally, it has partnered with Canon to innovate new imaging technologies for the patient care sector.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

Theraptosis is a biopharmaceutical company that designs and develops various drugs for cancer and neurodegenerative diseases. It also offers research and development programs covering anti-angiogenesis, targeted tumor cell killing, auto-immunity, and neuroprotection. Theraptosis was founded in 2001 and is based in Romainville, France.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor and electronic applications, focusing on damascene through silicon vias and MEMS. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, the company is based in Massy, France. Aveni's core offerings include Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been successfully implemented in manufacturing for processes at and below the 14 nm node and for high aspect ratios. Aveni collaborates with various research and development centers and leading global manufacturers, leveraging its expertise in surface science, chemistry, electrochemistry, and materials science to enhance device performance and yield in the semiconductor and renewable energy sectors.

StreamCore is a prominent provider of visibility and performance control solutions designed for managing interactive applications and real-time communications, such as VoIP and video, over wide area networks (WAN) and local area networks (LAN). The company's products offer enterprises comprehensive visibility across network performance, applications, and communication channels, all accessible from a single centralized management console. StreamCore's solutions uniquely integrate visibility with advanced performance control, allowing for efficient monitoring and reporting. This integration enhances the management of application delivery and ensures rapid deployment while maintaining cost-effectiveness for organizations.

AlchiMedics is focused on the implementation of electro-grafting technology for implantable biomedical applications. Its technology is used for fast healing post drug-eluting-stent implantation procedures. AlchiMedics was founded in 2007 and is based in Massy, France.